A Study of LY3314814 in Participants With Liver Impairment

• Status: Withdrawn
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether LY3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. Participants will be on study for 11 days with follow-up about 7 days afterward.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: AstraZeneca

Criteria

Inclusion Criteria:

• Have a Body Mass Index (BMI) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at the time of screening

Exclusion Criteria:

• Have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina

• Have moderate or severe vitiligo or any other clinically significant disorder of skin or hair pigmentation

• Have acute unstable neuropsychiatric disease

• Have active or uncontrolled neurologic disease, or clinically significant head injury